SCHEMBL19769026

SCHEMBL19769026

CC(C)c1cccnc1C=NO

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGF23 Q9GZV9 1/20 0.44
▸ GABRA1 P14867 3/20 0.39
▸ GABRB2 P47870 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP3A4 P08684 3/20 0.36
▸ GABRG2 P18507 2/20 0.36
▸ GABRB3 P28472 2/20 0.36
▸ FAAH O00519 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ GABRB1 P18505 1/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ GABRA5 P31644 1/20 0.36
▸ GABRA3 P34903 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19880563 1.00 FGF23 (0.44) FGF23GABRA1GABRB2ALDH1A1CYP3A4
SCHEMBL19124254 0.84 GABRA1 (0.36) FGF23GABRA1GABRB2CYP3A4GABRG2
SCHEMBL19779547 0.83 TSHR (0.43) FGF23GABRA1GABRB2ALDH1A1CYP1A2
SCHEMBL20621440 0.81 FGF23 (0.39) FGF23ALDH1A1LMNACYP1A2HPGD
SCHEMBL20621421 0.77 FGF23 (0.38) FGF23ALDH1A1
SCHEMBL21645883 0.76 CTH (0.54) FGF23ALDH1A1SLC6A2RRM2CTH
SCHEMBL21645884 0.76 CTH (0.54) FGF23ALDH1A1SLC6A2RRM2CTH
SCHEMBL2082260 0.76 GABRA1 (0.39) GABRA1GABRB2ALDH1A1CYP3A4GABRG2
SCHEMBL19880468 0.76 GABRA1 (0.39) GABRA1GABRB2CYP3A4GABRG2GABRB3
SCHEMBL12371007 0.76 GABRA1 (0.39) GABRA1GABRB2CYP3A4GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9896432-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2018-02-20 — — US disclosed
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 FGF23 194/4885GABRA1 322/4885GABRB2 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback